TERT and thyroid gland carcinoma: Thus far, BRAFV600E and TERT [13]/p53 [198] mutations are the main molecular prognostic biomarkers [199] used along with clinicopathological factors such as age, extra-thyroid tumor spread, lymph node and distant metastases and increasing tumor size in thyroid cancer [200].